• Active, not recruiting

NCT03975907: Phase 1/2 - Clinical Trial to Evaluate CT053 in Patients With RRMM (LUMMICAR STUDY 1)

Updated: May 26

(LUMMICAR STUDY 1)

CT053

NCT03975907: Phase 1/2 - Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)


This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT053 CAR-BCMA T in patients with relapsed and/or refractory multiple myeloma.


Sponsor

CARsgen Therapeutics Co., Ltd


Collaborators

Beijing Chao Yang Hospital

The First Affiliated Hospital of Soochow University

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Tianjin Medical University General Hospital

First Affiliated Hospital of Zhejiang University

Beijing Hospital

Shanghai Tongji Hospital, Tongji University School of Medicine

First Affiliated Hospital of Wenzhou Medical University

Xiangya Hospital of Central South University

Peking University People's Hospital

Qilu Hospital of Shandong University

Sun Yat-sen University

First Affiliated Hospital, Sun Yat-Sen University

 

ClinicalTrials.gov Identifier: NCT03975907


Open Label, Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Fully Human Anti-BCMA Chimeric Antibody Receptor Autologous T Cell (CAR T)in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)


First Posted : June 5, 2019


Click here for details on Clinicaltrials.gov

 

Anti-BCMA-targeting CAR-T Cells (Code C176023)

Anti-BCMA-targeting CAR-T Cells (Code C176023)

CART - BCMA : National Cancer Institute


Genetic: CAR-BCMA T cells

autologous anti-BCMA-CAR-4-1BB-CD3zeta-expressing T cells CT053

BCMA Car-T (CT053)

CAR-BCMA T cells CT053

CT053


Drug: Fludarabine

Drug: Cyclophosphamide

 

CARsgen Presents Updated Research Results on BCMA CAR T-cell Product (CT053) at 2021 ASH Annual Meeting


Poster #2821: Sustainable Efficacy and Safety Results from LUMMICAR STUDY 1: A Phase 1/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma


Poster #1751: Integrated Analysis of B-cell Maturation Antigen-Specific CAR T Cells (CT053) in Relapsed and Refractory Multiple Myeloma Subjects by High-Risk Factors

 

704.Cellular Immunotherapies: Clinical| November 5, 2021

Integrated Analysis of B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Relapsed and Refractory Multiple Myeloma Subjects By High-Risk Factors

https://ashpublications.org/blood/article/138/Supplement%201/1751/480716/Integrated-Analysis-of-B-Cell-Maturation-Antigen



704.Cellular Immunotherapies: Clinical| November 5, 2021

Sustainable Efficacy and Safety Results from Lummicar Study 1: A Phase 1/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma

https://ashpublications.org/blood/article/138/Supplement%201/2821/481343/Sustainable-Efficacy-and-Safety-Results-from

 

Location

China

China, Beijing: Beijing Chaoyang hospital

China, Jiangsu: The First Affiliated Hospital Of Soochow University








Posts Archive